WallStSmart

Broadcom Inc (AVGO)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Broadcom Inc generates 8% more annual revenue ($68.28B vs $63.32B). AVGO leads profitability with a 36.6% profit margin vs 11.8%. AVGO appears more attractively valued with a PEG of 0.93. AVGO earns a higher WallStSmart Score of 78/100 (B+).

AVGO

Strong Buy

78

out of 100

Grade: B+

Growth: 9.3Profit: 9.5Value: 5.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.59

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AVGO.

PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVGO6 strengths · Avg: 9.3/10
Market CapQuality
$2.04T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
33.4%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
36.6%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
44.9%10/10

Strong operational efficiency at 44.9%

PEG RatioValuation
0.938/10

Growing faster than its price suggests

Revenue GrowthGrowth
29.5%8/10

Revenue surging 29.5% year-over-year

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

AVGO3 concerns · Avg: 2.7/10
Altman Z-ScoreHealth
1.594/10

Distress zone — elevated risk

P/E RatioValuation
84.0x2/10

Premium valuation, high expectations priced in

Price/BookValuation
25.5x2/10

Trading at 25.5x book value

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : AVGO

The strongest argument for AVGO centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 36.6% and operating margin at 44.9%. Revenue growth of 29.5% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : AVGO

The primary concerns for AVGO are Altman Z-Score, P/E Ratio, Price/Book. A P/E of 84.0x leaves little room for execution misses.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

AVGO profiles as a growth stock while PFE is a value play — different risk/reward profiles.

AVGO carries more volatility with a beta of 1.44 — expect wider price swings.

AVGO is growing revenue faster at 29.5% — sustainability is the question.

AVGO generates stronger free cash flow (8.0B), providing more financial flexibility.

Bottom Line

AVGO scores higher overall (78/100 vs 55/100), backed by strong 36.6% margins and 29.5% revenue growth. PFE offers better value entry with a 29.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Broadcom Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Broadcom Inc. is an American designer, developer, manufacturer and global supplier of a wide range of semiconductor and infrastructure software products. Broadcom's product offerings serve the data center, networking, software, broadband, wireless, and storage and industrial markets.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?